Please find more information on our management team, as well as financial information here.
This page has been designed to comply with the requirements of
Rule 26 of the AIM Rules for Companies- "Company information disclosure". The
website was last updated on 19 March 2012.
| Company information | Documentation and announcements |
|---|---|
| Business description | Public documents |
| Directors and responsibilities | Financial reports |
| Incorporation and operations | Articles of Association |
| Advisors | Shareholder communications |
|
ISSUED SHARES Number of shares in issue 63,119,601
|
|
MAJOR SHAREHOLDERS
Information correct as at 19/03/2012 |
|
November 2003. |
|
OWNERSHIP Publicly traded on AiM of London Stock Exchange. |
|
PROFILE Proximagen is a biotechnology company focused on drug development for diseases of the Central Nervous System (CNS). |
|
MISSION STATEMENT Discoveries for life™. We are committed to bringing novel drugs and innovative new treatments to CNS disorders as rapidly as possible, bringing new hope to the patients and value to our shareholders. |
|
PIPELINE Proximagen's pipeline now comprises a broad range of programmes derived from in-house discovery activities, outright purchase of assets, and purchases of assets through corporate acquisition on success-based terms. |
|
GROUP COMPANIES The Proximagen Group consists of Proximagen
Limited and Cambridge Biotechnology Limited |
|
REGISTERED ADDRESS Proximagen Group plc
|
Proximagen Group plc is registered in England and Wales with registration number 05333020
Proximagen's VAT number is 864 1401 41